Article Versions Notes

Alexeeva EI, Dvoryakovskaya TM, Nikishina IP, Zholobova ES, Matkava VG, Krekhova EA, Raupov RK, Bukhanova DV, Egorova AN, Grishin SA, et al. Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period. Pharmaceuticals. 2026; 19(1):79. https://doi.org/10.3390/ph19010079

Alexeeva, Ekaterina I., Tatiana M. Dvoryakovskaya, Irina P. Nikishina, Elena S. Zholobova, Valeriya G. Matkava, Elizaveta A. Krekhova, Rinat K. Raupov, Daria V. Bukhanova, Alina N. Egorova, Sergey A. Grishin, and et al. 2026. "Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period" Pharmaceuticals 19, no. 1: 79. https://doi.org/10.3390/ph19010079

Alexeeva, E. I., Dvoryakovskaya, T. M., Nikishina, I. P., Zholobova, E. S., Matkava, V. G., Krekhova, E. A., Raupov, R. K., Bukhanova, D. V., Egorova, A. N., Grishin, S. A., Samsonov, M. Y., & Kostik, M. M. (2026). Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period. Pharmaceuticals, 19(1), 79. https://doi.org/10.3390/ph19010079